To determine the clinical importance of immunophenotypes in adult acute lymphoblastic leukemia (ALL), we prospectively studied 76 patients with this condition. Before treatment, lymphoblasts were tested for reactivity with monoclonal antibodies to B-cell, T-cell, and myeloid (My) antigens. Unexpectedly, myeloid antigens (MCS-2 or MY9) were identified in 25 patients (33 percent), usually in conjunction with B-cell or T-cell antigens. Among My+ patients, 15 (60 percent) expressed B-cell antigens (B+T-My+); all 6 tested had rearranged immunoglobulin genes. Five patients (20 percent) expressed T-cell antigens (B-T+My+), and one My+ patient expressed both B-cell and T-cell antigens. Only myeloid antigens (B-T-My+) were expressed in four patients (16 percent); three who were tested had germ-line immunoglobulin and T-cell-receptor gene configurations. Although no significant differences in presenting clinical features were found, My+ patients had fewer complete remissions than My- patients (35 vs. 76 percent, P less than 0.01). No differences in response or survival were observed between My+ and My- patients expressing T-cell antigens. However, among those expressing B-cell antigens, My+ patients had fewer complete remissions (29 vs. 71 percent, P = 0.02) and shorter survival (P = 0.03; median, 8.1 vs. greater than 26 months). These findings indicate that expression of myeloid antigen identifies a high-risk group of patients with adult ALL for whom alternative forms of treatment should be investigated.
This article has been cited by other articles:
Vitale, A., Guarini, A., Ariola, C., Meloni, G., Perbellini, O., Pizzuti, M., De Gregoris, C., Mettivier, V., Pastorini, A., Pizzolo, G., Vignetti, M., Mandelli, F., Foa, R.
(2007). Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. haematol
92: 342-348
[Abstract][Full Text]
Murakami, H., Yokoyama, A., Kondo, K., Nakanishi, S., Kohno, N., Miyake, M.
(2005). Circulating Aminopeptidase N/CD13 Is an Independent Prognostic Factor in Patients with Non-Small Cell Lung Cancer. Clin. Cancer Res.
11: 8674-8679
[Abstract][Full Text]
Czuczman, M. S., Dodge, R. K., Stewart, C. C., Frankel, S. R., Davey, F. R., Powell, B. L., Szatrowski, T. P., Schiffer, C. A., Larson, R. A., Bloomfield, C. D.
(1999). Value of Immunophenotype in Intensively Treated Adult Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8364. Blood
93: 3931-3939
[Abstract][Full Text]
Wetzler, M., Dodge, R. K., Mrozek, K., Carroll, A. J., Tantravahi, R., Block, A. W., Pettenati, M. J., Beau, M. M. L., Frankel, S. R., Stewart, C. C., Szatrowski, T. P., Schiffer, C. A., Larson, R. A., Bloomfield, C. D.
(1999). Prospective Karyotype Analysis in Adult Acute Lymphoblastic Leukemia: The Cancer and Leukemia Group B Experience. Blood
93: 3983-3993
[Abstract][Full Text]
Putti, M. C., Rondelli, R., Cocito, M. G., Arico, M., Sainati, L., Conter, V., Guglielmi, C., Cantu-Rajnoldi, A., Consolini, R., Pession, A., Zanesco, L., Masera, G., Biondi, A., Basso, G.
(1998). Expression of Myeloid Markers Lacks Prognostic Impact in Children Treated for Acute Lymphoblastic Leukemia: Italian Experience in AIEOP-ALL 88-91 Studies. Blood
92: 795-801
[Abstract][Full Text]
Borkhardt, A., Cazzaniga, G., Viehmann, S., Valsecchi, M. G., Ludwig, W. D., Burci, L., Mangioni, S., Schrappe, M., Riehm, H., Lampert, F., Basso, G., Masera, G., Harbott, J., Biondi, A.
(1997). Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials. Blood
90: 571-577
[Abstract][Full Text]
McKinney, W. P., Young, M. J., Hartz, A., Bi-Fong Lee, M.
(1989). The Inexact Use of Fisher's Exact Test in Six Major Medical Journals. JAMA
261: 3430-3433
[Abstract]
Previous
